CD4⁺CD25⁺ regulatory T cells control induction of autoimmune hemolytic anemia

Amina Mqadmi, Xiaoying Zheng, and Karina Yazdanbakhsh

Complement Biology, New York Blood Center, New York, USA.

Correspondence should be addressed to:
Karina Yazdanbakhsh, PhD
Complement Biology
New York Blood Center
310, E 67th Street
New York, NY 10021
Tel: 212-570-3383
FAX: 212-570-3195
email: kyazdanbakhsh@nybloodcenter.org

This study was supported in part by grants from the NIH R01 HL69102, and the American Heart Association Grant-in-Aid Heritage Affiliate.

Running title: CD4⁺CD25⁺ regulatory T cells in AIHA

Total text word count: 1208

Amina Mqadmi: Performed research
Xiaoying Zheng: Performed research
Karina Yazdanbakhsh: Designed and performed research
Abstract

Autoimmune hemolytic anemia (AIHA) is the result of increased destruction of red blood cells (RBCs) due to the production of autoantibodies and can be life-threatening. To study mechanisms that trigger AIHA, we used the Marshall-Clarke and Playfair model of murine AIHA, in which mice repeatedly immunized with rat RBCs develop erythrocyte autoantibodies as well as rat-specific alloantibodies. We analyzed the role of CD25+ T regulatory subsets in controlling AIHA in C57/Bl6 mice using antibody depletion studies. Treatment with anti-CD25 antibody, but not isotype control prior to immunization with rat RBCs increased the incidence of AIHA from 30% to 90%. Adoptive transfer of purified splenic population of CD4+CD25+, but not CD4+CD25- cells from immunized mice into naïve recipients prevented the induction of autoantibody production. Altogether, our data establishes a critical role for CD4+CD25+ cells for control of AIHA which may help to establish therapeutic strategies for treatment of AIHA.

Word count: 148

Key words: autoimmune hemolytic anemia, autoantibodies, induction of autoimmune disease, T regulatory cells, CD4+CD25+, reticulocytosis, adoptive transfer, mouse model of AIHA, rat RBC.
Introduction

AIHA is an autoimmune disease in which RBCs are destroyed prematurely due to the production of antibodies against the patient’s own red cells.1 The most common form of AIHA is characterized by presence of “warm” type autoantibodies, which are IgG type and react optimally at 37° C causing RBC destruction extravascularly by tissue macrophages.1 Playfair and Marshall-Clarke described a mouse model of AIHA, in which repeated injections with rat RBCs result in the development of autoantibodies against self RBCs and a disease process similar to warm type AIHA in man with evidence of anemia, reticulocytosis, shortened survival of RBCs and a direct Coombs positive state.2 As expected, the mice develop rat-specific xenoantibodies, thus providing an inbuilt control for the autoantibody response.3,4 Spleen cells or T cells from mice immunized with rat RBCs transferred to naïve recipients suppress the subsequent induction of autoantibodies, but not the xenoantibody response, indicating a regulatory mechanism in the induction of autoantibody response.4,5 The nature of this suppressive activity remains to be elucidated.

T-regulatory CD4+ cell populations characterized by co-expression of CD25 (interleukin-2 receptor alpha chain) have been shown to play an important role in the generation and maintenance of peripheral tolerance.6 Although studies have not directly addressed the role of CD4+ CD25+ T cells in the development of AIHA per se, it was noted that about 25% of older CD25 knockout mice develop autoimmune disorders, including hemolytic anemia.7

We have used the Marshall-Clarke and Playfair model of murine AIHA to determine the role of CD4+ CD25+ T regulatory cells for induction of AIHA. Depletion studies using anti-CD25 increased the incidence of AIHA in C57/Bl6 mice from 30% to 90%. In addition, adoptive
transfer of purified CD4⁺CD25⁺, but not CD4⁺CD25⁻ cells, from immunized mice prevented the induction of AIHA. Altogether, our data demonstrate the importance of CD4⁺CD25⁺ cells for control and induction of AIHA.

**Materials and Methods**

*Immunization regimen for induction of AIHA*. Rat RBCs were isolated from whole rat blood using histopaque (Sigma-Aldrich) gradient and adjusted to 10⁹ cell/ml. Female C57/Bl6 mice aged between 8 and 10 weeks were immunized intraperitoneally with 2 x10⁸ rat RBCs in 200 µl RPMI on a weekly basis.

*In vivo depletion with anti-CD25*. C57/BL6 mice were given 500 µg of anti-CD25 (clone 7D4, BD Pharmingen, San Diego, CA) on a weekly basis for a total of 3 weeks, eight hours prior to immunization with rat RBCs. As control, mice were treated with 500 µg of isotype control rat IgG2b (BD Pharmingen) followed by immunization with rat RBCs or with 500 µg of anti-CD25 alone without the rat RBC immunization regimen.

*Detection and measurement of auto- and alloantibodies and complete hematological analysis.* Blood samples (25 µl) by retro-orbital sinus bleeding were obtained on a weekly basis, 5 days after each immunization. Reticulocyte counts were performed using Advia 120 Hematology System (Bayer, Tarrytown, NY). In addition, levels of IgG sensitization (autoantibodies) on the RBCs were determined by flow cytometry using FITC-conjugated anti-mouse IgG (Vector Laboratories, Burlingham, California). For analysis of rat RBC specific xenoantibodies, rat RBCs were incubated with diluted mouse plasma for 1 hour at 37⁰ C and after several washes, were stained with FITC conjugated anti-mouse IgG. Analysis of levels of anti- double stranded
DNA was performed with plasma diluted at a final concentration of 1 in 100 using a commercially available ELISA kit according to manufacturer’s instructions (Alpha Diagnostic, San Antonio, TX).

**Transfusion studies:** Mouse RBCs obtained from naïve female C57/Bl6 mice were labeled with PKH-26 (Sigma) and injected by the tail-vein into control mice or those who had developed AIHA. Blood samples were obtained by retro-orbital sinus bleeding at the time points indicated after transfusion and the clearance of fluorescent RBCs was measured by flow cytometry as previously described.

**Adoptive cell transfer.** Splenocytes from animals immunized with rat RBCs on a weekly basis for 12 weeks were harvested, stained with PE-labeled anti-CD4 (clone) and PE-Cy7-labeled anti-CD25 (clone 7D4) (both from BD Pharmingen) and purified using high speed sorting (MoFlo; Dako Cytomation) to separate CD4+CD25- and CD4+CD25hi cells. Approximately 2 x 10^5 cells in 0.2 ml of PBS were injected intravenously into 10 week old female C57/Bl6 recipient mice. After one day, the mice were immunized with rat RBCs on a weekly basis.

**Statistical analysis.** The significance of differences between groups of mice were calculated using a single factor Anova test, and only p values less than 0.05 were considered as significant.

## Results and Discussion

Approximately 30% of female C57/Bl6 mice immunized on a weekly basis with rat RBCs develop AIHA, as evidenced by presence of red cell specific autoantibodies on their RBCs, increased levels of reticulocytes and increased destruction of transfused syngeneic mouse RBCs (Fig. 1A, B, C). However, all the mice developed rat RBC specific xenoantibodies (Fig. 1D), consistent with previous data. To examine whether CD4+CD25+ cells play a role in the
induction of AIHA in this experimental model, we depleted mice (n=10) of CD25+ cells prior to
immunization with rat RBCs on a weekly basis for three weeks. Administration of an anti-CD25
antibody almost completely depleted CD4+CD25+ cells in C57/Bl6 mice (Fig. 2A).
Immunization of rat RBCs in the depleted mice increased the frequency of AIHA to 90% (Fig.
2B,C), demonstrating a critical role for T regulatory CD25+ cells in development of this type of
autoimmune disease. Weekly treatment with an isotype control antibody followed by rat RBC
immunization (n=5) (Fig. 2B) or treatment with anti-CD25 alone (n=5) (Fig. 2B,C) for three
weeks did not result in increased incidence of AIHA as observed in the anti-CD25/rat RBC
immunized mice.
We also measured the levels of anti-ds DNA characteristic of systemic autoimmune disease and
found significantly elevated levels in anti-CD25/rat RBC immunized mice, as compared to
control mice treated with only rat RBCs or treated with anti-CD25 alone (Fig. 2D). In addition,
the levels of xenoantibodies against rat RBCs in anti-CD25/rat RBC immunized mice were
elevated as compared to mice treated with rat RBCs alone (Fig. 2E), consistent with a heightened
immune hypersensitive state.
Splenocytes taken from mice immunized with rat RBCs at weekly intervals for 12 weeks and
transferred to naïve recipients suppress the subsequent induction of autoantibodies.4 To
determine if CD4+CD25+ cells play a role in this suppressive activity in this animal model, we
adoptively transferred CD4+CD25+ or CD4+CD25− sorted cells from mice immunized with rat
RBCs on a weekly basis for 12 weeks, into naïve C57/Bl6 mice. One day after the transfer, mice
were immunized with rat RBCs on a weekly basis. Analysis of the mice after 9 immunizations
demonstrated that autoantibody production was completely suppressed in mice adoptively
transferred with CD4+CD25+(n=5), but not CD4−CD25− (n=6) cells (Fig. 2F). Analysis of anti-rat
RBC levels indicated that CD4⁺CD25⁺ adoptively transferred mice developed xenoantibodies as effectively as control mice (Fig. 2G), demonstrating that CD4⁺CD25⁺ suppressive activity is autoantibody response specific.

Although there may be multiple factors that contribute to the induction of AIHA, our data indicates that defective suppressive activity of CD4⁺CD25⁺ cells could play an essential role in the onset and/or maintenance of this autoimmune disease. Current therapies for AIHA include administration of immunosuppressive drugs together with transfusion or splenectomy in patients with relapsing cases which typically control, rather than cure, the disease. The immunotherapeutic potential of CD4⁺CD25⁺ cells may represent a more effective strategy for treatment of AIHA.

**Acknowledgements**

We thank Yazan Abdullah for his technical assistance in setting up the immunization protocol and performing the initial measurements of the auto-and xeno-antibodies. We are grateful to Gabriel Alespeti (NYBC) for cells sorting and advice on some of the FACS analysis. We wish to thank Dr. Barry Coller (Rockefeller University) for allowing us to use his Advia 120 hematology system and are especially grateful to Thomas Hoffman for his help with the instrument.
References


Fig. (1). Development of AIHA in mice treated on a weekly basis with rat RBCs. Female C57/Bl6 mice aged 8-10 weeks were immunized on a weekly basis with rat RBCs for 10 weeks. (A) Levels of IgG-specific autoantibodies on mouse RBCs were measured by flow cytometry and are expressed as percentage of background unstained cells. The bar in each panel represents the mean values and n is the number of mice in each group. The autoantibody levels in rat immunized compared to control uninjected mice were significantly higher (p<0.05). (B) Numbers of circulating reticulocytes in mice expressed as a percentage. There was significant difference in the reticulocyte counts between the rat immunized group and control uninjected mice (p<0.05). (C) RBCs obtained from mice immunized with rat RBCs (n=5) or control mice (n=4) were fluorescently labeled with PKH-26 and injected intravenously into an equivalent numbers of C57Bl/6 naïve mice. At times indicated, venous blood was sampled and analyzed by flow cytometry for the fraction of fluorescent RBCs. To show the clearance kinetics, injected RBCs at time 1’ post-injection were taken as 100% and the remaining RBCs were calculated at different time points as the average for each group of mice (error bars depict the standard error of the mean SEM). The difference at all points between the mice receiving RBCs from rat immunized mice and those receiving control RBCs was calculated as p=0.04. (D) Levels of IgG-specific anti-rat xenoantibodies in plasma was measured by first incubating rat erythrocytes with diluted mouse plasma (1 in 50000) followed by staining with FITC-conjugated anti-mouse IgG. The analysis was performed by flow cytometry and is presented as relative fluorescent units on the y axis.

Fig. 2. Antibody depletion and adoptive transfer studies to study the role of CD4+ CD25+ T cells in induction of AIHA. (A) A representative flow cytometric analysis of peripheral blood leukocytes obtained from mice before and 4 days after intraperitoneal injection of 500 µg of
monoclonal anti-CD25 (clone 7D4). Cells were stained with PE-conjugated monoclonal anti-
CD4 (GK1.5) and PE-Cy7-conjugated anti-CD25 (clone PC61.5). (B) Levels of IgG-specific autoantibodies on RBCs from mice expressed as percentage of background unstained cells. The difference between rat RBC/anti-CD25 and rat RBC alone groups was calculated as $p=4 \times 10^{-9}$ and between rat RBC/anti-CD25 and rat RBC/isotype control groups as $p=0.0009$. As expected, rat RBC/isotype control group was different from control no injection group ($p=1.5 \times 10^{-4}$), but no differences were found between rat RBC/isotype control and rat RBC alone groups ($p=0.9$). In addition, there were no differences between no injection and anti-CD25 alone injected groups ($p=0.5$). (C) The circulating reticulocyte counts of the mice are expressed as a percentage of total blood. The difference between rat RBC/anti-CD25 and rat RBC alone groups was $p=4 \times 10^{-9}$. No differences were found between no injection and anti-CD25 alone groups ($p=0.2$). (D) The relative levels of anti-ds DNA in plasma of mice was measured by ELISA using a commercially available kit and is presented in OD units on the y axis. The difference between rat RBC/anti-
CD25 and rat RBC alone groups was calculated as $p=0.0005$. (E) The presence of IgG specific xenoantibodies to rat RBCs in plasma from mice at 3 weeks post immunization was measured using diluted plasma (1 in 1000) followed by analysis using flow cytometry and is presented as relative fluorescent units on y axis. The difference between rat RBC/anti-CD25 and rat RBC alone groups was calculated as $p=0.04$. (F) About $2 \times 10^5$ CD4+CD25$^{hi}$ or CD4$^+$CD25$^-$ sorted cells were adoptively transferred into naïve C57Bl/6 female mice followed by weekly immunization with rat RBCs for 9 weeks. Levels of IgG autoantibodies on mouse RBCs as well as (G) xenoantibodies (IgG) to rat RBCs are shown for individual mice. The difference in autoantibody levels between mice adoptively transferred with CD4$^+$CD25$^{hi}$ and those that
received CD4⁺CD25⁻ was calculated as $p=0.04$. However, there were no differences in the xenoantibody levels between these two groups ($p=0.4$).
Fig. 2

A. No treatment + anti-CD25

B. % IgG sensitization

C. % reticulocytes

D. CD65

E. anti-rat RBCs (Fluorescent units)

F. % IgG sensitization

G. Anti-rat RBC IgG (Fluorescent units)
CD4+CD25+ regulatory T cells control induction of autoimmune hemolytic anemia

Amina Mqadmi, Xiaoying Zheng and Karina Yazdanbakhsh

Advance online articles have been peer reviewed and accepted for publication but have not yet appeared in the paper journal (edited, typeset versions may be posted when available prior to final publication). Advance online articles are citable and establish publication priority; they are indexed by PubMed from initial publication. Citations to Advance online articles must include digital object identifier (DOIs) and date of initial publication.